Actelion Pharmaceuticals Ltd - Company Profile
Powered by
All the data and insights you need on Actelion Pharmaceuticals Ltd in one report.
- Save hours of research time and resources with
our up-to-date Actelion Pharmaceuticals Ltd Strategy Report
- Understand Actelion Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Actelion Pharmaceuticals Ltd (Actelion), a subsidiary of Johnson & Johnson, is a biopharmaceutical company, which discovers, develops and commercializes innovative treatments for diseases with considerable unmet medical needs. The company focuses on the development of treatments for pulmonary arterial hypertension (PAH). Its PAH franchise products include Tracleer (bosentan), Opsumit (macitentan), Veletri (epoprostenol for injection), Ventavis (iloprost)\, and Uptravi (selexipag). Its specialty product includes Zavesca (miglustat). Actelion also offers approved treatments for diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, multiple sclerosis and digital ulcers in patients with systemic sclerosis. The company offers its products in various countries across Europe, besides Japan, China, Russia, and the US, among others. Actelion is headquartered in Allschwil, Switzerland.
Actelion Pharmaceuticals Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Tracleer (bosentan) | Tracleer |
Ventavis (iloprost) | Ventavis |
Opsumit (macitentan) | Opsumit |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
Competitor Comparison
Key Parameters | Actelion Pharmaceuticals Ltd | F. Hoffmann-La Roche Ltd | Santhera Pharmaceuticals Holding AG | Mymetics Corp | Alpex Pharma SA |
---|---|---|---|---|---|
Headquarters | Switzerland | Switzerland | Switzerland | Switzerland | Switzerland |
City | Allschwil | Basel | Pratteln | Epalinges | Mezzovico |
State/Province | Basel-Landschaft | - | - | - | Tessin |
No. of Employees | - | 103,605 | 46 | 8 | - |
Entity Type | Private | Public | Public | Public | Private |
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Andre C. Muller | Executive Vice President; Chief Financial Officer | Senior Management | 2013 | 58 |
Nicholas Franco | Executive Vice President; Chief Business Development Officer | Senior Management | 2011 | 57 |
Alessandro Maresta | Head - Medical Affairs; Vice President | Senior Management | - | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer